TransEnterix to initiate Senhance Surgical System program in Netherlands

TransEnterix (NYSEMKT:TRXC) is up 9% premarket after entering into an agreement with Maastricht University Medical Center+ to lease and utilize a Senhance Surgical System, in pediatric minimally invasive surgery.

The Senhance Surgical System is intended to be used for laparoscopic surgery in the abdomen, pelvis and limited uses in the thoracic cavity excluding the heart and greater vessels.

In February 2020, TransEnterix received CE Mark approval for expanded indication of use to include pediatric patients.


See also  Americans watching a 'lot more' TV, pointing to new streaming normal - study

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.